Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Oligometastatic Prostate Carcinoma 1Oligo-metastatic Prostate Carcinoma 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cance 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 7Nivolumab 6pembrolizumab 4lenvatinib 3cabozantinib 3Axitinib 3vorolanib 2fludarabine 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Cyclophosphamide 2Biopsy 2toripalimab 1tivozanib 1sintilimab 1pazopanib 1fludarabine phosphate 1enzalutamide 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1atezolizumab 1abiraterone 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × abiraterone × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡